DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study presented here at ARVO.
George Ousler, Ora Inc. senior vice president of anterior segment, said that Mitotech’s SkQ1 ophthalmic solution is a “novel therapeutic approach to dry eye.”
DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study presented here at ARVO.
George Ousler, Ora Inc. senior vice president of anterior segment, said that Mitotech’s SkQ1 ophthalmic solution is a “novel therapeutic approach to dry eye.”
